Intellia Therapeutics and SparingVision Collaboration
Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.
Intellia Therapeutics is to grant SparingVision exclusive rights to Intellia . . .
This content is for paid subscribers.
Impacting News October 14, 2021